(-)-1-(Benzofuran-2-yl)-2-propylaminopentane enhances locomotor activity in rats due to its ability to induce dopamine release.

[1]  F. Yoneda,et al.  Structure-activity studies leading to (-)1-(benzofuran-2-yl)-2-propylaminopentane, ((-)BPAP), a highly potent, selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain. , 2001, Bioorganic & medicinal chemistry.

[2]  F. Yoneda,et al.  (−)1‐(Benzofuran‐2‐yl)‐2‐propylaminopentane, [(−)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain , 1999, British journal of pharmacology.

[3]  Kathyrne Mueller,et al.  Locomotor Stereotypy Produced by Dexbenzetimide and Scopolamine Is Reduced by SKF 83566, Not Sulpiride , 1998, Pharmacology Biochemistry and Behavior.

[4]  J. Knoll,et al.  (-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain. , 1998, Pharmacology & toxicology.

[5]  K. Mueller,et al.  Amphetamine-Induced Locomotor Stereotypy in Rats Is Reduced by a D 1 but not a D 2 Antagonist , 1997, Pharmacology Biochemistry and Behavior.

[6]  M. Miyamoto,et al.  Effects of 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1 -H-1-benzazepin-8-yl)-1-propanone fumarate (TAK-147), a novel acetylcholinesterase inhibitor, on impaired learning and memory in animal models. , 1996, The Journal of pharmacology and experimental therapeutics.

[7]  J. Knoll,et al.  Phenylethylamine and tyramine are mixed-acting sympathomimetic amines in the brain. , 1996, Life sciences.

[8]  J. Knoll,et al.  High performing rats are more sensitive toward catecholaminergic activity enhancer (CAE) compounds than their low performing peers. , 1996, Life sciences.

[9]  J. Knoll,et al.  (-)Deprenyl and (-)1-phenyl-2-propylaminopentane, [(-)PPAP], act primarily as potent stimulants of action potential-transmitter release coupling in the catecholaminergic neurons. , 1996, Life sciences.

[10]  M. Rogawski,et al.  Effects of D1 and D2 dopamine receptor antagonists and catecholamine depleting agents on the locomotor stimulation induced by dizocilpine in mice , 1995, Behavioural Brain Research.

[11]  R. Kostrzewa,et al.  Dopamine receptor supersensitivity , 1995, Neuroscience & Biobehavioral Reviews.

[12]  J. Knoll,et al.  Enhanced catecholaminergic and serotoninergic activity in rat brain from weaning to sexual maturity: rationale for prophylactic (-)deprenyl (selegiline) medication. , 1995, Life sciences.

[13]  M. Briley,et al.  Noradrenergic mechanisms in Parkinson's disease. , 1993, Trends in pharmacological sciences.

[14]  A. Norman,et al.  Long-term sensitization of apomorphine-induced rotation behavior in rats with dopamine deafferentation or excitotoxin lesions of the striatum , 1993, Pharmacology Biochemistry and Behavior.

[15]  P. B. Silverman.  On-off effects of dopamine receptor agonists in the hemi-parkinsonian rat. , 1993, European journal of pharmacology.

[16]  F. Colpaert.  Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat , 1987, Neuropharmacology.

[17]  H. Fibiger.  The Neurobiological Substrates of Depression in Parkinson’s Disease: A Hypothesis , 1984, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[18]  H. Kuribara.  Strain differences to the effects of central acting drugs on Sidman avoidance response in Wistar and Fischer 344 rats , 1982, Pharmacology Biochemistry and Behavior.

[19]  J. Dambrosia,et al.  Lisuride in parkinsonism , 1981, Neurology.

[20]  G. Hertting,et al.  FLUVOXAMINE, A SPECIFIC 5‐HYDROXYTRYPTAMINE UPTAKE INHIBITOR , 1977, British journal of pharmacology.

[21]  P. Riederer,et al.  IMPLICATIONS OF COMBINED TREATMENT WITH 'MADOPAR' AND L-DEPRENIL IN PARKINSON'S DISEASE A Long-term Study , 1977, The Lancet.

[22]  P. Leigh,et al.  Treatment of parkinsonism with bromocriptine. , 1974, Lancet.

[23]  K. E. Moore,et al.  Dopamine: Release from the Brain in vivo by Amantadine , 1971, Science.

[24]  M. Besson,et al.  Increased synthesis and release of dopamine in the striatum of the rat after amantadine treatment. , 1970, European journal of pharmacology.

[25]  R. Young,et al.  Amantadine in the treatment of Parkinson's disease. , 1969, JAMA.

[26]  C J Niemegeers,et al.  Is it possible to predict the clinical effects of neuroleptic drugs (major tranquillizers) from animal data? , 1966, Arzneimittel-Forschung.

[27]  C. Niemegeers,et al.  IS IT POSSIBLE TO PREDICT THE CLINICAL EFFECTS OF NEUROLEPTIC DRUGS (MAJOR TRANQUILLIZERS) FROM ANIMAL DATA?I. "NEUROLEPTIC ACTIVITY SPECTRA" FOR RATS. , 1965, Arzneimittel-Forschung.

[28]  A. Barbeau.  The pathogenesis of Parkinson's disease: a new hypothesis. , 1962, Canadian Medical Association journal.

[29]  O. Hornykiewicz,et al.  [The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia]. , 1961, Wiener klinische Wochenschrift.

[30]  O. Hornykiewicz,et al.  Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. , 1960, Parkinsonism & related disorders.

[31]  T. Rao,et al.  Effects of a novel cholinergic ion channel agonist SIB-1765F on locomotor activity in rats. , 1997, The Journal of pharmacology and experimental therapeutics.

[32]  T. Rao,et al.  Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-DOPA in the reserpine model of Parkinson's disease in rats. , 1997, The Journal of pharmacology and experimental therapeutics.

[33]  H. Mayberg,et al.  Depression in Parkinson's disease: a biochemical and organic viewpoint. , 1995, Advances in neurology.

[34]  S. Yasar,et al.  The pharmacology of 1-phenyl-2-propylamino-pentane (PPAP), a deprenyl-derived new spectrum psychostimulant. , 1992, Archives internationales de pharmacodynamie et de therapie.

[35]  Y. Agid,et al.  Biochemical substrates of mental disturbances in Parkinson's disease. , 1984, Advances in neurology.

[36]  U. Ungerstedt,et al.  6-hydroxydopamine-induced degeneration of the nigrostriatal dopamine pathway: the turning syndrome. , 1976, Pharmacology & therapeutics. Part B: General & systematic pharmacology.

[37]  U. Ungerstedt,et al.  Antiparkinsonian drugs and dopaminergic neostriatal mechanisms: studies in rats with unilateral 6-hydroxydopamine (=6-OH-DA)-induced degeneration of the nigro-neostriatal DA pathway and quantitative recording of rotational behaviour. , 1976, Pharmacology & therapeutics. Part B: General & systematic pharmacology.

[38]  A. Carlsson.  Monoamine-depleting drugs. , 1975, Pharmacology & therapeutics. Part B: General & systematic pharmacology.

[39]  Schwab Rs,et al.  Apomorphine in Parkinson's disease. , 1951 .